David A. Siegel Satsuma Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.7 - $1.07 $85,190 - $130,219	121,700 Added 79.91%	274,000 $191,000
Q4 2022 Feb 14, 2023	BUY	$0.61 - $5.06 $71,675 - $594,550	117,500 Added 337.64%	152,300 $137,000
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $11,732 - $22,260	-2,800 Reduced 7.45%	34,800 $209,000
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $75,110 - $124,700	-29,000 Reduced 43.54%	37,600 $156,000
Q1 2022 May 16, 2022	SELL	$3.78 - $5.32 $80,892 - $113,848	-21,400 Reduced 24.32%	66,600 $253,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $196,295 - $295,152	-47,300 Reduced 34.96%	88,000 $396,000
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $214,288 - $338,424	-47,200 Reduced 25.86%	135,300 $630,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $190,560 - $287,825	-39,700 Reduced 17.87%	182,500 $1.29 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $134,815 - $211,810	29,500 Added 15.31%	222,200 $1.31 Million
Q4 2020 Feb 16, 2021	SELL	$3.56 - $5.09 $86,508 - $123,687	-24,300 Reduced 11.2%	192,700 $888,000
Q3 2020 Nov 16, 2020	BUY	$3.85 - $28.47 $835,450 - $6.18 Million	217,000 New	217,000 $844,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.